Skip to content
10-Q

Quarterly Report

Faeth Therapeutics, Inc. FTH SNSE

0001193125-26-225333

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 1.34M sh
Shares Diluted Q1 2026 · Mar 31, 2026 1.3M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 1.26M sh
Capex Q1 2026 · Mar 31, 2026 $6K
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$10.73M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$7.09M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $152.33M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $8.67M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$137.29M
Stockholders Equity Q1 2026 · Dec 31, 2025 $18.59M
Stockholders Equity Q1 2026 · Mar 31, 2025 $31.99M
Stockholders Equity Q1 2026 · Dec 31, 2024 $38.39M
Current Liabilities Q1 2026 · Mar 31, 2026 $14.19M
Current Liabilities Q1 2026 · Dec 31, 2025 $4.25M
Total Liabilities Q1 2026 · Mar 31, 2026 $14.19M
Total Liabilities Q1 2026 · Dec 31, 2025 $4.31M
Current Assets Q1 2026 · Mar 31, 2026 $204.23M
Current Assets Q1 2026 · Dec 31, 2025 $21.51M
Total Assets Q1 2026 · Mar 31, 2026 $205.38M
Total Assets Q1 2026 · Dec 31, 2025 $22.9M
Eps Diluted Q1 2026 · Mar 31, 2026 −$131.45
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$5.45
Eps Basic Q1 2026 · Mar 31, 2026 −$131.45
Eps Basic restated Q1 2026 · Mar 31, 2025 −$5.45
Sga Expense Q1 2026 · Mar 31, 2026 $19.71M
Sga Expense Q1 2026 · Mar 31, 2025 $3.55M
Net Income Q1 2026 · Mar 31, 2026 −$170.24M
Net Income Q1 2026 · Mar 31, 2025 −$6.86M
Operating Income Q1 2026 · Mar 31, 2026 −$170.63M
Operating Income Q1 2026 · Mar 31, 2025 −$7.27M